Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (57)	9/26/2001 1:34:42 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 139

Looks like DHA not ready for clinic yet. Progenics Awarded NIH Grant for Experimental Drug to Prevent Brain Damage From Stroke - Published Study Shows Therapeutic Activity of Novel Form of Vitamin C in Stroke Model - TARRYTOWN, N.Y., Sept. 26 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - news) announced today that it had been awarded approximately $300,000 from the National Institutes of Health (NIH) for the development of dehydroascorbic acid (DHA) as a therapy for ischemic stroke. The award is a Phase I Small Business Innovation Research (SBIR) grant. The grant will support continued preclinical efficacy studies, early manufacturing scale-up, and formulation development. The Company also announced the publication of a scientific article in the latest issue of the Proceedings of the National Academy of Sciences (PNAS) describing how DHA significantly decreased brain damage and neurological deficits when administered up to three hours after a stroke in an animal model. Progenics is the exclusive licensee of DHA and related intellectual property from the Sloan Kettering Institute for Cancer Research. Wilder